alexa

GET THE APP

Interview | Josef WagnernbspJournal of Gastrointestinal
ISSN: 2161-069X

Journal of Gastrointestinal & Digestive System
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google Scholar citation report
Citations : 1384

Journal of Gastrointestinal & Digestive System received 1384 citations as per Google Scholar report

Journal of Gastrointestinal & Digestive System peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page
 
Josef Wagner
Josef Wagner

Josef Wagner
Research Officer, Enteric Virus Group
Murdoch Childrens Research Institute
Royal Children Hospital
Australia
Tel. 613-8341-6450
Fax 613-8341-6449
Read Interview session with Josef Wagner

 
Biography

Joseph Wagner is a Post Doc. at the Enteric Virus Group, Murdoch Childrens Research Institute at the Royal Childrens Hospital Melbourne, Australia. At the current position he is leading together with their primary lab head and mentor Dr. Carl Kirkwood the project "Understanding the role of infectious agents as a trigger of Crohns disease in children with early onset disease".  This project aims to characterize bacteria and viruses that may act as a trigger for Crohn’s disease in children. One model of Crohn’s disease suggests that it is initiated in susceptible individuals by an infectious agent, or agents, capable of triggering tissue injury that is persistent and immune-mediated. They have conducted a series of preliminary experiments designed to identify an infectious agent in mucosal biopsy tissue that was obtained at initial endoscopic examination of children with suspected Crohn’s disease. Since his employment,he has supervised two honours student, one MD scholar and co-supervised 1 PhD student. Currently, he is responsible for the laboratory training of two junior gastroenterologists doing a PhD.
 

 
Research Interest

Joseph Wagner main research interest is paediatric Crohn’s disease. In their research they are analysing gut mucosal biopsies for bacteria and viruses (known and unknown) which might play an important role in the development of Crohn’s disease.  They have investigated the role of Mycobacterium, Pseudomonas, and Burkholderia bacteria in biopsy specimens. They also genotyped all their patient cohort for the most common 34 SNPs associated with Crohn’s disease and performed association studies with bacterial infection. Currently, he is using Roche 454 next generation sequencing platform to analyse bacterial changes in post operative endoscopic adult Crohn’s disease recurrence patients. Also, Roche 454 is currently used to analyse the viral population in biopsy specimens of paediatric Crohn’s disease patients. In summary, his expertise is in microbial involvements in Crohn’s disease, genetic implication in Crohn’s disease and metagenomic analysis of the gut flora using latest bio-informatics software including, MOTHUR and MEGAN.
 

Interview

1. How many years have you been associated with the current research?
15 years

2. What is the research topic you are working on now?
 Host-microbial interaction
 microRNA and RNA-associated molecules
 Endoscopy

3. What are attributes for a quality article?
 I identified effective molecules produced by bacteria (probiotics). The molecules are expected to be used as a new drug for intestinal disorders (Fujiya, Cell H&M, 2007; Segawa, Fujiya, PlosOns, 2011).
 I identified that miR-18a directly bound to oncogenic protein hnRNP A1 and degraded the protein through autophagolysosomal pathway, leading apoptosis of cancer cells (Fujiya, Oncogene, in press).
 Image-enhanced endoscopies are useful for diagnosing intestinal disorders including colon cancer, lymphoma and inflammatory bowel diseases (Sato, Fujiya, Endoscopy, 2011; Kashima, Nata, Fujiya, GUT, 2011; Fujiya, Gastrointestinal Endoscopy, 2013; Fujiya, Gastrointestinal Endoscopy, 2014, e.g.).

4. Do you have any research funding (NIH or other national funding) now?
Some national funds are supporting my researches.

5. When did you become an editor of OMICS Journal?
Around 3 years ago

6. Where can the journal find the maximum scope in terms of niche?
Novel insights concerning both clinical and basic science

7. What is your greatest career accomplishment?
Associate professor

8. How does the published scientific content assist the potential researchers?
Cost down

9. What is the purpose of serving as an editor?
To promote the journal and learn research topics from submitted journal.

10. Do you have any patents?
Yes.

11. Have you contributed any editorials or papers (any types) to OMICS Journals in the past two years?
No.

12. Do you plan to contribute any editorials or papers to OMICS Journals in the next year?
Yes.

13. How would you define your experience with OMICS Group?
Clinical and basic research of the intestinal tract

14. Your opinion on conducting Editorial Board meetings at related Conferences?
I don’t think the meetings are useful to promote the journal.

15. Would you recommend OMICS to your friends or colleagues?
Yes.

16. How do you differentiate Journal of Gastrointestinal & Digestive System with other journals in the field?
It would be better to ask young investigators to submit articles with very low fee.

Top